VBI Vaccines Inc. news
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced it has entered into a refinanced and upsized debt facility of up to $100 million with its existing lender, K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.
Under the terms of the agreement, $50 million is immediately available to VBI upon clo
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (Valneva) and VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) today announced a partnership in select European markets for the marketing and distribution of PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)], the only 3-antigen hepatitis B vaccine approved in Europe.
Under the terms of the agreement, specialty vaccine company Valneva will promote and distribute PreHevbri throughout sel
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that John Dillman has been appointed as the Company’s Chief Commercial Officer. Mr. Dillman will be responsible for leading VBI’s commercial strategy, sales, and sales operations, including the commercialization of VBI’s 3-Ant
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new data from a follow-up analysis of a subset of participants from the pivotal Phase 3 study (PROTECT) of the Company’s 3-antigen prophylactic hepatitis B (HBV) vaccine, were presented in an oral presentation at The International Liver Congress™ 2022 (ILC),
VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting results from its annual general meeting of shareholders held on June 22, 2022 (the "Meeting").
The total number of common shares of the Company ("Common Shares") represented by shareholders ("Shareholders") present in person or represented by proxy at the Meeting was an aggregate of 179,53
- FDA Orphan Drug Designation reflects urgent need for new therapies for glioblastoma (GBM) patients
- Next steps for development of VBI-1901 :
- Q3 2022: Expected initiation of randomized, controlled clinical study in recurrent GBM patients with potential to support accelerated approval application
- Q4 2022: Expected initiation of randomized, controlled evaluation in primary GBM patients as part of INSIGhT adaptive platform trial
V
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI’s President and CEO, will participate in an analyst-led fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022.
Presentation Details
- Event: Jefferi
- Median overall survival and 18-month overall survival data continue to show improvements over historical controls1
- One patient remains on protocol progression-free beyond two years, with a sustained 93% tumor reduction relative to baseline
- Next steps :
- Recurrent GBM: randomized, controlled evaluation with potential to support accelerated approval application expected to initiate in Q3 2022
- Primary GBM: randomized, controlled evaluatio
- PreHevbri is the only approved 3-antigen hepatitis B vaccine for adults in the United Kingdom
- Approval follows the European Commission’s marketing authorisation, granted in April 2022
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the UK Medicines and Healthcare Products R
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that an abstract highlighting long-term durability of immune response data following vaccination with VBI’s 3-antigen hepatitis B (HBV) vaccine has been accepted for oral presentation at The International Liver Congress™ 2022 (ILC), the Annual Meeting of the Euro